Efficacy of methylprednisolone in children with severe community acquired pneumonia

Pediatric Pulmonology

Volumn 48, Issue 2, 2013, Pages 168-175

  Nagy, Bela ^a   Gaspar, Imre ^a   Papp, Agnes ^a   Bene, Zsolt ^a   Nagy Jr, Bela ^a   Voko, Zoltan ^b   Balla, Gyorgy ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

childhood; community acquired pneumonia; corticosteroid; imipenem

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CEPHALOSPORIN DERIVATIVE; DICLOFENAC; IMIPENEM; MACROLIDE; METHYLPREDNISOLONE; PARACETAMOL; PLACEBO;

ARTICLE; CHILD; CHILD HOSPITALIZATION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84872414822     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22574     Document Type: Article

References (42)

1. van der Poll T, Opal SM,., Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-1556.
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T,. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
3. Li ST, Tancredi DJ,. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010; 125: 26-33.
4. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Advisory Committee on Immunization Practices. MMWR Recomm Rep 2000;49:1-35.
5. Ampofo K, Bender J, Sheng X, Korgenski K, Daly J, Pavia AT, Byington CL,. Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection. Pediatrics 2008; 122: 229-237.
6. Nascimento-Carvalho CM, Cardoso MR, Brandileone MC, Ferrero F, Camargos P, Berezin E, Ruvinsky R, Sant'anna C, March MF, Feris-Iglesias J, Maggi R, Benguigui Y, CARIBE Group. Penicillin/ampicillin efficacy among children with severe pneumonia due to penicillin-resistant pneumococcus (MIC = 4 microg ml(-1)). J Med Microbiol 2009; 58: 1390-1392.
7. Chetty K, Thomson AH,. Management of community-acquired pneumonia in children. Paediatr Drugs 2007; 9: 401-411.
8. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR,. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
9. Feldman C, Anderson R,. Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs 2011; 71: 131-153.
10. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
11. Godon N, Denizot S, Podevin G, Caillon J, Potel G, Christophe Roze, Gras-Le J, Guen C,. Effectiveness of linezolid and imipenem association in the treatment of severe community-acquired pneumonia in children: two case reports. Scand J Infect Dis 2006; 38: 381-383.
12. van de Beek D, de Gans J, McIntyre P, Prasad K,. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007; 1: CD004405.
13. Prasad K, Singh MB,. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; 1: CD002244.
14. Bodmann KF,. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005; 51: 227-233.
15. Sibila O, Luna CM, Agustí C, Baquero S, Gando S, Patrõn JR, Morato JG, Absi R, Bassi N, Torres A,. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 2008; 32: 1037-1046.
16. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F,., Vogeser M, American College of Critical Care Medicine. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 6: 1937-1949.
17. Montõn C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP,. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999; 27: 1745-1753.
18. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU,. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-248.
19. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J,. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30: 951-956.
20. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG,. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181: 975-982.
21. Salluh JI, Põvoa P, Soares M, Castro-Faria-Neto HC, Bozza FA, Bozza PT,. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008; 12: R76.
22. Weiss AK, Hall M, Lee GE, Kronman MP, Sheffler-Collins S, Shah SS,. Adjunct corticosteroids in children hospitalized with community-acquired pneumonia. Pediatrics 2011; 127: e255-e263.
23. Lee JH, Loh TF,. Continuous hydrocortisone infusion in severe pediatric community-acquired pneumonia (CAP). Pediatr Int 2010; 52: e125-e127.
24. Clifford V, Tebruegge M, Vandeleur M, Curtis N,. Question 3: can pneumonia caused by penicillin-resistant Streptococcus pneumoniae be treated with penicillin ? Arch Dis Child 2010; 95: 73-77.
25. Adam D,. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50: 1-5.
26. BTS Guidelines for the management of community acquired pneumonia in childhood. Thorax 2002; i1-i24.
27. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6: 2-8.
28. Hajdu E, Matuz M, Benko R, Ordas A, Nagy E,. An 8-year evaluation of antibiotic consumption and antibiotic resistance among Streptococcus pneumoniae from in- and out-patients in Szeged. Hungary J Chemother 2007; 19: 519-527.
29. Dobay O,. Molecular characterisation, antibiotic sensitivity and serotyping of hungarian Streptococcus pneumoniae isolates. Acta Microbiol Immunol Hung 2008; 55: 395-407.
30. Picazo JJ,. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines. Clin Microbiol Infect 2009; 15: 4-6.
31. Lionakis MS, Kontoyiannis DP,. Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828-1838.
32. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S,. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999; 54: 51-55.
33. Kolsuz M, Erginel S, Alataş O, Alataş F, Metintaş M, Uçgun I, Harmanci E, Colak O,. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration 2003; 70: 615-622.
34. Gorman SK, Slavik RS, Marin J,. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007; 41: 1233-1237.
35. Greos LS, Vichyanond P, Bloedow DC, Irvin CG, Larsen GL, Szefler SJ, Hill MR,. Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Am Rev Respir Dis 1991; 144: 586-592.
36. Silva PL, Garcia CS, Maronas PA, Cagido VR, Negri EM, Damaceno-Rodrigues NR, Ventura GM, Bozza PT, Zin WA, Capelozzi VL, Pelosi P, Rocco PR,. Early short-term versus prolonged low-dose methylprednisolone therapy in acute lung injury. Eur Respir J 2009; 33: 634-645.
37. Agustí C, Rañõ A, Filella X, González J, Moreno A, Xaubet A, Torres A,. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003; 123: 488-498.
38. Ioanas M, Ferrer M, Cavalcanti M, Ferrer R, Ewig S, Filella X, de la Bellacasa JP, Torres A,. Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. Crit Care Med 2004; 32: 938-945.
39. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters JC, Bos WJ, Biesma DH,. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 2023-2030.
40. Schaaf B, Kruse J, Rupp J, Reinert RR, Droemann D, Zabel P, Ewig S, Dalhoff K,. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007; 30: 517-524.
41. Salluh JI, Bozza FA, Soares M, Verdeal JC, Castro-Faria-Neto HC, Lapa E, Silva JR, Bozza PT,. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest 2008; 134: 947-954.
42. Salluh JI, Verdeal JC, Mello GW, Araújo LV, Martins GA, de Sousa Santino M, Soares M,. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 2006; 32: 595-598.